Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-13T18:40:29.396Z Has data issue: false hasContentIssue false

PW01-248 - Topiramate as An Adjunct In Alcohol Detoxification Process

Published online by Cambridge University Press:  17 April 2020

T. Paparrigopoulos
Affiliation:
Psychiatry, University of Athens School of Medicine, Athens, Greece
E. Tzavellas
Affiliation:
Psychiatry, University of Athens School of Medicine, Athens, Greece
D. Karaiskos
Affiliation:
Psychiatry, University of Athens School of Medicine, Athens, Greece
E. Papalias
Affiliation:
Psychiatry, University of Athens School of Medicine, Athens, Greece
E. Drabalos
Affiliation:
Psychiatry, University of Athens School of Medicine, Athens, Greece
I. Liappas
Affiliation:
Psychiatry, University of Athens School of Medicine, Athens, Greece

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

Anticonvulsants have been used for the treatment of affective and anxiety symptoms secondary to alcohol abuse as well as craving. In this open label study we investigated efficacy of topiramate as an adjunct in alcohol detoxification; end targets were anxiety, depression and in obsessive-compulsive drinking.

Methods

Two groups matched for age, alcohol consumption and demographic characteristics, were treated either with psychotherapy (n=43) or psychotherapy and topiramate (n=43). Subjects were assessed twice (baseline and after a 4-6 week detoxification period) by the Hamilton Anxiety Rating Scale, the Hamilton Depression Rating Scale, and the Obsessive Compulsive Drinking Scale. T-tests were used for comparisons between groups.

Results

Following detoxification, psychopathology significantly subsided in both groups; however, improvement was more robust in the topiramate group (table 1).

 HDRS admissionHDRS dischargeHARS admissionHARS dischargeOCDS admissionOCDS discharge
Topiramate group39.2 ± 4.26.7 ± 4.3*33.9 ± 6.45.5 ± 6.5*42.3 ± 3.28.2 ± 3.3*
Control group38.7 ± 5.39.8 ± 7.4*32.3 ± 10.69.5 ± 6.5*41.5 ± 2.615.2 ± 2.4*

[Table 1]

Discussion

Topiramate in conjunction with a short-term psychotherapeutic approach may help the alcohol detoxification process by minimizing craving and subjective physical discomfort. Moderate to severe anxiety and depressive symptoms with concomitant poor functioning were present in all subjects before treatment. Following 4-6 weeks of alcohol detoxification, a considerable improvement in terms of anxiety and depressive symptoms was observed in both groups. However, in our sample, a significantly more robust decrease was recorded in the topiramate augmentation group. Consequently, topiramate can be of potential help in this population and can be used as an alternative among other treatment options.

Type
Substance related disorders
Copyright
Copyright © European Psychiatric Association 2009
Submit a response

Comments

No Comments have been published for this article.